Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • April 27, 2025

Jaiswal V, Hanif M, Mashkoor Y, Prasad T, Fonarow GC. Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2025 Apr 14;4(5):101696. doi: 10.1016/j.jacadv.2025.101696. Epub ahead of print. PMID: 40286362.

Tags: Cardiology/Epi, Publications

Late-in-life treadmill-training mitigates gut microbiome imbalances and cardiovascular disease risk in mice

Cho JM, Park SK, Satheesh Babu AK, Mookherjee S, Hansen M, Petersen C, Zhong Y, Jalili T, Robeson MS, Whankade UD, Anandh Babu PV, Symons[...]

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

New strategies for valve replacement and interventional options in adults with congenital heart disease: new insights from Euro-ACHD 2025

Butera G, Chessa M, Gaio G, Kempny A, Uebing A, Michielon G, Aboulhosn J, Giamberti A, Hoschtitzky A, d'Udekem Y. New strategies for valve replacement[...]